協和キリンの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2017/11/09 | 2,152 | 2,165 | 2,090 | 2,116 | -36 | -1.7% | 1,729,600 |
| 2017/11/08 | 2,167 | 2,171 | 2,131 | 2,152 | -42 | -1.9% | 1,416,100 |
| 2017/11/07 | 2,146 | 2,197 | 2,132 | 2,194 | +50 | +2.3% | 1,232,800 |
| 2017/11/06 | 2,172 | 2,181 | 2,129 | 2,144 | -11 | -0.5% | 845,200 |
| 2017/11/02 | 2,130 | 2,157 | 2,118 | 2,155 | +49 | +2.3% | 1,587,200 |
| 2017/11/01 | 2,107 | 2,112 | 2,082 | 2,106 | +18 | +0.9% | 1,328,100 |
| 2017/10/31 | 2,095 | 2,096 | 2,060 | 2,088 | -18 | -0.9% | 1,569,900 |
| 2017/10/30 | 2,108 | 2,112 | 2,079 | 2,106 | +13 | +0.6% | 2,404,700 |
| 2017/10/27 | 1,994 | 2,100 | 1,991 | 2,093 | +121 | +6.1% | 2,378,000 |
| 2017/10/26 | 1,984 | 1,997 | 1,960 | 1,972 | -24 | -1.2% | 1,229,500 |
| 2017/10/25 | 2,042 | 2,042 | 1,989 | 1,996 | -44 | -2.2% | 1,025,700 |
| 2017/10/24 | 2,030 | 2,044 | 2,023 | 2,040 | ±0 | ±0% | 655,200 |
| 2017/10/23 | 2,045 | 2,050 | 2,027 | 2,040 | +18 | +0.9% | 962,800 |
| 2017/10/20 | 2,020 | 2,039 | 2,009 | 2,022 | +3 | +0.1% | 954,000 |
| 2017/10/19 | 2,000 | 2,028 | 2,000 | 2,019 | +25 | +1.3% | 866,800 |
| 2017/10/18 | 2,000 | 2,001 | 1,985 | 1,994 | -4 | -0.2% | 1,019,100 |
| 2017/10/17 | 2,000 | 2,002 | 1,983 | 1,998 | +7 | +0.4% | 839,000 |
| 2017/10/16 | 1,973 | 1,996 | 1,967 | 1,991 | +10 | +0.5% | 791,600 |
| 2017/10/13 | 1,950 | 1,984 | 1,950 | 1,981 | +15 | +0.8% | 1,541,400 |
| 2017/10/12 | 1,984 | 1,984 | 1,965 | 1,966 | -12 | -0.6% | 710,800 |
| 2017/10/11 | 1,942 | 1,982 | 1,940 | 1,978 | +23 | +1.2% | 750,900 |
| 2017/10/10 | 1,939 | 1,956 | 1,928 | 1,955 | -5 | -0.3% | 914,000 |
| 2017/10/06 | 1,969 | 1,969 | 1,948 | 1,960 | ±0 | ±0% | 906,400 |
| 2017/10/05 | 1,960 | 1,961 | 1,946 | 1,960 | ±0 | ±0% | 738,900 |
| 2017/10/04 | 1,965 | 1,975 | 1,955 | 1,960 | -6 | -0.3% | 932,700 |
| 2017/10/03 | 1,918 | 1,968 | 1,908 | 1,966 | +52 | +2.7% | 1,312,200 |
| 2017/10/02 | 1,930 | 1,944 | 1,909 | 1,914 | ±0 | ±0% | 1,550,200 |
| 2017/09/29 | 1,882 | 1,914 | 1,875 | 1,914 | +26 | +1.4% | 1,493,400 |
| 2017/09/28 | 1,900 | 1,902 | 1,881 | 1,888 | -17 | -0.9% | 1,428,100 |
| 2017/09/27 | 1,937 | 1,948 | 1,892 | 1,905 | -11 | -0.6% | 1,230,300 |
| 2017/09/26 | 1,884 | 1,918 | 1,881 | 1,916 | +28 | +1.5% | 1,154,100 |
| 2017/09/25 | 1,894 | 1,897 | 1,874 | 1,888 | +11 | +0.6% | 1,291,800 |
| 2017/09/22 | 1,873 | 1,880 | 1,859 | 1,877 | +18 | +1% | 955,400 |
| 2017/09/21 | 1,852 | 1,877 | 1,848 | 1,859 | +16 | +0.9% | 1,012,900 |
| 2017/09/20 | 1,848 | 1,862 | 1,838 | 1,843 | -21 | -1.1% | 1,078,600 |
| 2017/09/19 | 1,847 | 1,867 | 1,842 | 1,864 | +26 | +1.4% | 1,325,100 |
| 2017/09/15 | 1,854 | 1,860 | 1,831 | 1,838 | -10 | -0.5% | 1,487,900 |
| 2017/09/14 | 1,891 | 1,896 | 1,848 | 1,848 | -58 | -3% | 1,411,400 |
| 2017/09/13 | 1,883 | 1,914 | 1,875 | 1,906 | +34 | +1.8% | 1,255,400 |
| 2017/09/12 | 1,872 | 1,877 | 1,853 | 1,872 | +17 | +0.9% | 992,700 |
| 2017/09/11 | 1,835 | 1,861 | 1,828 | 1,855 | +49 | +2.7% | 1,216,200 |
| 2017/09/08 | 1,786 | 1,818 | 1,785 | 1,806 | -9 | -0.5% | 2,609,400 |
| 2017/09/07 | 1,844 | 1,849 | 1,806 | 1,815 | -47 | -2.5% | 1,529,900 |
| 2017/09/06 | 1,853 | 1,869 | 1,838 | 1,862 | +11 | +0.6% | 1,010,500 |
| 2017/09/05 | 1,860 | 1,862 | 1,844 | 1,851 | -15 | -0.8% | 950,900 |
| 2017/09/04 | 1,919 | 1,924 | 1,865 | 1,866 | -83 | -4.3% | 1,467,000 |
| 2017/09/01 | 1,955 | 1,963 | 1,935 | 1,949 | +18 | +0.9% | 975,800 |
| 2017/08/31 | 1,905 | 1,939 | 1,904 | 1,931 | +35 | +1.8% | 1,081,800 |
| 2017/08/30 | 1,879 | 1,905 | 1,876 | 1,896 | +34 | +1.8% | 1,197,000 |
| 2017/08/29 | 1,855 | 1,866 | 1,848 | 1,862 | -8 | -0.4% | 655,300 |
1901～
1950
件表示中 / 3768件
類似銘柄と比較する
現在ご覧いただいている「協和キリン」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 協和キリン | 263,900円 | -3.5% | -11.3% | 2.27% | 24.24倍 | 1.64倍 |
|
キリン傘下。医薬品、バイオが主力。独自の抗体高活性化技術に強み。富士フイルムと提携 |
| アステラス薬 | 169,200円 | +0.9% | +380.2% | 4.61% | 23.31倍 | 2.00倍 |
|
医薬品国内２位。開発技術起点の研究開発体制。前立腺がん薬が柱。遺伝子・細胞治療技術育成 |
| 塩野義 | 258,000円 | +20.9% | +10.6% | 2.56% | 12.20倍 | 1.61倍 |
|
抗ＨＩＶ薬が大型製品に。感染症、疼痛・中枢神経領域に強み。米国に積極展開。欧州、アジア開拓 |
| エーザイ | 467,600円 | +0.1% | -3.4% | 3.42% | 31.79倍 | 1.57倍 |
|
神経系、がん領域に強み。認知症薬は米バイオジェンと、抗がん薬では米メルクと国際協業推進 |
| 小野薬 | 166,100円 | +0.6% | +43.3% | 4.82% | 11.65倍 | 1.00倍 |
|
医療用医薬品専業の中堅。自社開発品多い。先駆的がん免疫阻害剤「オプジーボ」が成長牽引 |
市場注目の銘柄
チャート関連のコラム
